Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

BREAK

Financiado

Blue light remote analgesia with K channels

Chronic pain (CP) is a medical condition affecting around 20% of adults in Europe, characterised by an abnormal duration of pain (> 12 weeks) originally initiated by a trauma or illness. Despite significant progress, CP remains ex... ver más

30/11/2021

UMIL

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MILANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-11-30

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

UMIL

150.00K€ | Lider

TIRUÑA

398.46K€ | Participante

Últimas noticias

02-12-2024: AGENCIA-VALENCIANA-D... En las últimas 48 horas el Organismo AGENCIA VALENCIANA D... ha otorgado 1 concesiones

02-12-2024: CDTI En las últimas 48 horas el Organismo CDTI ha otorgado 4 concesiones

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

Duración del proyecto: 24 meses Fecha Inicio: 2019-11-11
Fecha Fin: 2021-11-30

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MILANO

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Chronic pain (CP) is a medical condition affecting around 20% of adults in Europe, characterised by an abnormal duration of pain (> 12 weeks) originally initiated by a trauma or illness. Despite significant progress, CP remains extremely hard to treat, with only one-third to two-thirds of patients reporting adequate some pain relief. This situation is even worse for neuropathic pain (NP), a specific class of CP affecting 8% of global population and whose origin mostly depend on peripheral or central nervous damage or disorder, which leads the brain to interpret as pain normally non painful stimuli. NP is difficult to treat due to the large number of entities involved (cells, genes and proteins working in synergy), which makes it hard to rapidly diagnose the exact cause of pain. Drugs targeting the central nervous system (e.g. antidepressants and opioids) provide only partial pain relief and are nonspecific, also causing side effects like addiction, and nausea, thus restraining their adoption for prolonged treatments. BREAK is the first non-invasive inhibitory optogenetic tool specifically designed for NP treatment, with potential application to the whole spectrum of CP. BREAK is composed of a drug and an optical device. The protein BLINK2 is injected in the painful area using a genetically engineered virus, and respond to a specific blue light by silencing the addressed neuron. The lamp can be kept at some distance (cm) from the skin and no implant is required. Just some minutes of treatment results in hours of pain relief, making the invasiveness of BREAK far lower than actually existing solution. A first version of BREAK has already demonstrated in in-vivo experiments on rats. During this project we plan to further develop the treatment and explore its commercial potential. In particular, leveraging from the experience of different partners, we will constitute a fruitful stakeholder network, including Academic centers, hospitals, pharma companies and investor

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores